PMC7369376_01
CT scan of the thorax of Case one during the EGFR-KTI treatment and radiofrequency ablation. (A) A 2.2*2.0 cm tumor is seen in the left lobe of the lung on October 11, 2014. (B-D) After Icotinib Hydrochloride Tablets treatment, the local lesion was evaluated on January 23, 2015, on March 4, 2016, and on September 2, 2016. (E) Chest computed tomography scans of the patient during the first treatment of radiofrequency ablation on September 17, 2016. (F) After the first time treatment of radiofrequency ablation, chest CT enhancement scan (March 3, 2017) revealed complete ablation of local lesion. (G) The chest CT enhancement scan of local lesion on July 25, 2018 showed that the space occupying lesion enlarged and intensify. (H) Chest computed tomography scans of the patient during the second time treatment of radiofrequency ablation (August 16, 2018). A deployable needle is puncturing the tumor. (I) The local lesion was evaluated on April 23, 2019 via chest CT enhancement scan. A mitigated and non-enhanced lesion was observed which implied that the efficacy was achieved as complete ablation.
OTT-13-6789-g0001.jpg
PMC7369376_01_OTT-13-6789-g0001.jpg
F0001
Chest CT examination showed a 2.2*2.0 cm mass in the left upper lobe of the lung (Figure 1A). Follow-up CT showed mitigated local lesion (Figures 1B and C) and a partial response (PR) was achieved. Tablets (Figure 1D). The patient was secondly hospitalized for radiofrequency ablation (Olympus 200-T20, 20 W and 9 KJ for 10 minutess) in September 2016 (Figure 1E). The chest CT scan was reexamined in the outpatient department and the result revealed a shrunken tumor miraculously in the left upper lobe of the lung after six months (Figure 1F). The patient achieved stable disease after radiofrequency ablation and continuous first generation of EGFR TKI until May 2018 (Figure 1G). Until April 2019, the efficacy was evaluated as complete ablation (Figure 1I).
PMC7369376_02
CT scan of the thorax of Case two during the EGFR-KTI treatment and radiofrequency ablation. (A) Baseline before treatment of gefitinib: a pulmonary space occupying lesion is visible in the right upper lobe on March 25, 2017. (B) After 2 months of EGFR-TKI therapy, the lung tumor was smaller than before. (C) After 6 months of EGFR-TKI therapy, the lung tumor was a ittle larger than before. (D) Chest computed tomography scans of the patient during the treatment of radiofrequency ablation on October 26, 2017. (E and F) After the treatment of radiofrequency ablation, chest computed tomography scans (E, April 26, 2018; F, May 28, 2019) the lung tumor was decreased.
OTT-13-6789-g0002.jpg
PMC7369376_02_OTT-13-6789-g0002.jpg
F0002
A 72-year-old woman, with no history of smoking, was diagnosed with lung adenocarcinoma (T1N0Mx) in March 2017 (Figure 2A). Regular follow-up in the outpatient department after two months showed a decrease in pulmonary lesion (Figure 2B). Yet, the patient was admitted to the hospital in October 2017 because chest CT scan revealed a progression of lung lesion (Figure 2C). The local radiofrequency ablation (Olympus 200-T20, 20 Wm and 9 KJ for 10 minutes) for treatment of oligoprogressive lesions in combination with continuation of the original TKIs was accepted (Figure 2D). Regular follow-up of chest CT indicated that the lesion was stable until May 2019 (Figures 2E and F).